These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 1152617)
1. Studies of the inhibition of dopamine beta hydroxylase by thiono-sulfur containing compounds. Catignani GL; Neal RA Life Sci; 1975 Jun; 16(12):1915-21. PubMed ID: 1152617 [No Abstract] [Full Text] [Related]
2. Inhibition of dopamine beta-hydroxylase by anti-thyroid agents, methimazole and propylthiouracil. Hidaka H; Nagasaka A Biochem Pharmacol; 1977 Jun; 26(11):1092-3. PubMed ID: 880264 [No Abstract] [Full Text] [Related]
3. 1-(Thienylalkyl)imidazole-2(3H)-thiones as potent competitive inhibitors of dopamine beta-hydroxylase. McCarthy JR; Matthews DP; Broersma RJ; McDermott RD; Kastner PR; Hornsperger JM; Demeter DA; Weintraub HJ; Whitten JP J Med Chem; 1990 Jul; 33(7):1866-73. PubMed ID: 2362264 [TBL] [Abstract][Full Text] [Related]
4. Multisubstrate inhibitors of dopamine beta-hydroxylase. 1. Some 1-phenyl and 1-phenyl-bridged derivatives of imidazole-2-thione. Kruse LI; Kaiser C; DeWolf WE; Frazee JS; Garvey E; Hilbert EL; Faulkner WA; Flaim KE; Sawyer JL; Berkowitz BA J Med Chem; 1986 Dec; 29(12):2465-72. PubMed ID: 3783606 [TBL] [Abstract][Full Text] [Related]
5. Carbon disulfide. II. A proposed mechanism for the action of carbon disulfide on dopamine beta-hydroxylase. McKenna MJ; DiStefano V J Pharmacol Exp Ther; 1977 Aug; 202(2):253-66. PubMed ID: 886465 [No Abstract] [Full Text] [Related]
6. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Stanley WC; Li B; Bonhaus DW; Johnson LG; Lee K; Porter S; Walker K; Martinez G; Eglen RM; Whiting RL; Hegde SS Br J Pharmacol; 1997 Aug; 121(8):1803-9. PubMed ID: 9283721 [TBL] [Abstract][Full Text] [Related]
7. Inhibitors of dopamine beta-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones. Ross ST; Kruse LI; Ohlstein EH; Erickson RW; Ezekiel M; Flaim KE; Sawyer JL; Berkowitz BA J Med Chem; 1987 Aug; 30(8):1309-13. PubMed ID: 3612682 [TBL] [Abstract][Full Text] [Related]
8. 1-(substituted-benzyl)imidazole-2(3H)-thione inhibitors of dopamine beta-hydroxylase. Burke BJ; Hopfinger AJ J Med Chem; 1990 Jan; 33(1):274-81. PubMed ID: 2296023 [TBL] [Abstract][Full Text] [Related]
9. Increase of brain levels of tryptophan induced by inhibition of dopamine beta-hydroxylase (EC 1.14.2.1). Johnson GA; Kim EG J Neurochem; 1973 Jun; 20(6):1761-4. PubMed ID: 4719318 [No Abstract] [Full Text] [Related]
10. Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure. Hegde SS; Friday KF Curr Pharm Des; 1998 Dec; 4(6):469-79. PubMed ID: 10197057 [TBL] [Abstract][Full Text] [Related]
11. Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine beta-hydroxylase. 4. Structure-activity relationships at the copper binding site. Kruse LI; Kaiser C; DeWolf WE; Finkelstein JA; Frazee JS; Hilbert EL; Ross ST; Flaim KE; Sawyer JL J Med Chem; 1990 Feb; 33(2):781-9. PubMed ID: 2299645 [TBL] [Abstract][Full Text] [Related]
12. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein. Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540 [TBL] [Abstract][Full Text] [Related]
13. Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: comparison with nepicastat. Bonifácio MJ; Sousa F; Neves M; Palma N; Igreja B; Pires NM; Wright LC; Soares-da-Silva P Eur J Pharmacol; 2015 Mar; 751():50-8. PubMed ID: 25641750 [TBL] [Abstract][Full Text] [Related]
14. Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site. Kruse LI; Kaiser C; DeWolf WE; Frazee JS; Ross ST; Wawro J; Wise M; Flaim KE; Sawyer JL; Erickson RW J Med Chem; 1987 Mar; 30(3):486-94. PubMed ID: 3820219 [TBL] [Abstract][Full Text] [Related]
15. Different patterns of inhibition of dopamine-beta-hydroxylase by cysteine. Izumi H; Oyama H; Hayakari M; Ozawa K Jpn J Pharmacol; 1976 Apr; 26(2):263-6. PubMed ID: 940232 [No Abstract] [Full Text] [Related]
16. Irreversible inhibition of dopamine-beta-hydroxylase by cysteine. Izumi H; Oyama H; Hayakari M; Ozawa H Biochem Pharmacol; 1976 Feb; 25(4):488-9. PubMed ID: 938576 [No Abstract] [Full Text] [Related]
17. A slow-tight binding inhibitor of dopamine beta-monooxygenase: a transition state analogue for the product release step. Dharmasena SP; Wimalasena DS; Wimalasena K Biochemistry; 2002 Oct; 41(41):12414-20. PubMed ID: 12369831 [TBL] [Abstract][Full Text] [Related]
18. Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase. Kruse LI; Kaiser C; DeWolf WE; Frazee JS; Erickson RW; Ezekiel M; Ohlstein EH; Ruffolo RR; Berkowitz BA J Med Chem; 1986 Jun; 29(6):887-9. PubMed ID: 3712378 [No Abstract] [Full Text] [Related]
19. Effects of dopamine beta-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Sabbah HN; Stanley WC; Sharov VG; Mishima T; Tanimura M; Benedict CR; Hegde S; Goldstein S Circulation; 2000 Oct; 102(16):1990-5. PubMed ID: 11034950 [TBL] [Abstract][Full Text] [Related]